- Home
- CLLS vs SCD Comparison
CLLS vs SCD Comparison
Compare CLLS & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SCD
- Stock Information
- Founded
- CLLS 1999
- SCD 2003
- Country
- CLLS France
- SCD United States
- Employees
- CLLS N/A
- SCD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SCD Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- SCD Finance
- Exchange
- CLLS Nasdaq
- SCD Nasdaq
- Market Cap
- CLLS 143.4M
- SCD 272.7M
- IPO Year
- CLLS 2007
- SCD N/A
- Fundamental
- Price
- CLLS $2.12
- SCD $15.57
- Analyst Decision
- CLLS Buy
- SCD
- Analyst Count
- CLLS 1
- SCD 0
- Target Price
- CLLS $4.00
- SCD N/A
- AVG Volume (30 Days)
- CLLS 48.9K
- SCD 62.6K
- Earning Date
- CLLS 08-05-2025
- SCD 01-01-0001
- Dividend Yield
- CLLS N/A
- SCD 9.63%
- EPS Growth
- CLLS N/A
- SCD N/A
- EPS
- CLLS N/A
- SCD N/A
- Revenue
- CLLS $54,747,000.00
- SCD N/A
- Revenue This Year
- CLLS $48.52
- SCD N/A
- Revenue Next Year
- CLLS $5.17
- SCD N/A
- P/E Ratio
- CLLS N/A
- SCD N/A
- Revenue Growth
- CLLS 351.26
- SCD N/A
- 52 Week Low
- CLLS $1.10
- SCD $11.33
- 52 Week High
- CLLS $2.43
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- SCD 45.48
- Support Level
- CLLS $1.56
- SCD $15.58
- Resistance Level
- CLLS $1.49
- SCD $15.97
- Average True Range (ATR)
- CLLS 0.09
- SCD 0.23
- MACD
- CLLS 0.01
- SCD -0.01
- Stochastic Oscillator
- CLLS 80.00
- SCD 33.33
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.